Seegene Inc. said it began supplying its COVID-19 diagnostic tests worth 16,209,150 GBP to Scotland under a public procurement agreement, the largest diagnostic volume seen in that region since the pandemic. Compared to Seegene's annual sales tallied in Scotland, the supply contract is worth triple the volume in 2020, which came in at GBP 5,400,000 .Under the supplying deal, Seegene'sScotland dealership, Mast Group, will be supplying Allplex SARS CoV-2 to the National Health Care Scotland NSS, which will then be distributed to 9 hospitals including Royal Infirmary Edinburgh and Ninewell starting in April. Seegene's COVID-19 diagnostic test, the Allplex SARS CoV-2 Assay is a unique multiplex real-time PCR assay that can detect a total of five targets including four coronavirus genes (E gene, RdRp gene, N gene and S gene) and an exogenous control (entire process control) in a single reaction tube, allowing accurate results and maximize throughput for high volume testing. The diagnostic test previously acquired CE-IVD mark in June 2020. Seegene recently began exporting both Allplex SARS-CoV-2 Master Assay and Allplex SARS-CoV-2 Variants l Assay to over 20 countries around the world, including the hardest hit European countries including the UK, Italy, Germany as well as Chile after having acquired CE-IVD mark in March. Seegene's exceptional technological skills are being recognized once again through a series of public procurement agreements including the most recent tender deal secured in Italy via its subsidiary office, worth over EUR 89.3 million. Yi said Seegene hopes to realize additional market expansion soon through its aggressive marketing strategies elsewhere around the world.